[
  {
    "ts": "2025-12-22T07:44:00+00:00",
    "headline": "Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma",
    "summary": "TOKYO, December 22, 2025--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma",
    "url": "https://finance.yahoo.com/news/incyte-japan-announces-approval-minjuvi-074400718.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ed84d5fd-fcb1-373e-b789-f7ca1f8d788d",
      "content": {
        "id": "ed84d5fd-fcb1-373e-b789-f7ca1f8d788d",
        "contentType": "STORY",
        "title": "Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma",
        "description": "",
        "summary": "TOKYO, December 22, 2025--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma",
        "pubDate": "2025-12-22T07:44:00Z",
        "displayTime": "2025-12-22T07:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c27fd35707c901cdb0aec441b1142472",
          "originalWidth": 480,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ChRBZicrji_ojNmF.rMEzQ--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c27fd35707c901cdb0aec441b1142472.cf.webp",
              "width": 480,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hMv0OYFArHGmUBxQSrlGqA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c27fd35707c901cdb0aec441b1142472.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-japan-announces-approval-minjuvi-074400718.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-japan-announces-approval-minjuvi-074400718.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T07:42:00+00:00",
    "headline": "Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer",
    "summary": "TOKYO, December 22, 2025--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer",
    "url": "https://finance.yahoo.com/news/incyte-japan-announces-approval-zynyz-074200998.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "3fe9a272-8e01-3844-8c22-0619668eabb7",
      "content": {
        "id": "3fe9a272-8e01-3844-8c22-0619668eabb7",
        "contentType": "STORY",
        "title": "Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer",
        "description": "",
        "summary": "TOKYO, December 22, 2025--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer",
        "pubDate": "2025-12-22T07:42:00Z",
        "displayTime": "2025-12-22T07:42:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/9e7490c5fbe5987cc848cf8a97c6d954",
          "originalWidth": 480,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TWh3PAKao1a9LBW5w12jAg--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9e7490c5fbe5987cc848cf8a97c6d954.cf.webp",
              "width": 480,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DYnAnvety5RswY3V9rpCmA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9e7490c5fbe5987cc848cf8a97c6d954.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-japan-announces-approval-zynyz-074200998.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-japan-announces-approval-zynyz-074200998.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T14:03:00+00:00",
    "headline": "Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?",
    "summary": "Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "url": "https://finance.yahoo.com/news/incyte-incy-soars-5-5-140300380.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4119d0a3-ebc8-3da5-ae58-891a3d6d4b3a",
      "content": {
        "id": "4119d0a3-ebc8-3da5-ae58-891a3d6d4b3a",
        "contentType": "STORY",
        "title": "Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?",
        "description": "",
        "summary": "Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
        "pubDate": "2025-12-22T14:03:00Z",
        "displayTime": "2025-12-22T14:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ca1f35690cb2a67673dfbf8f52e2777c",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u6qRj2rwTBqPBpHnEtxPLg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca1f35690cb2a67673dfbf8f52e2777c.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rV3VlZrAMuUdZwWufmaq.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca1f35690cb2a67673dfbf8f52e2777c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-soars-5-5-140300380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-soars-5-5-140300380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "NRIX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]